Zala Varmegyei Szent Rafael Korhaz — Clinical Trial Site

55 Registered trials

21 Currently recruiting

Organisation

Zala Varmegyei Szent Rafael Korhaz

Location

Zalaegerszeg, Hungary

Identifier

ORG-100041954

Address

Zrinyi Miklos Utca 1, 8900, Hungary

Departments

#036008: Onkológiai Osztály
#2633: II. Belgyógyászat
2204 : Kardiológiai Osztály
3302:Aneszteziológiai és Intenzív Terápiás Osztály
3306; Onkológiai Osztály
Anesthesiology and Intensive Care
Belgyogyaszat
Cardiology
Department of Cardiology
Department of Intensive Therapy and Anaesthesiology
Department of Oncology
Department of Ophthalmology
HUN4: Szemészeti Osztály
Kardiologiai Osztaly
N/A
NA
Neurológiai Osztály
Oncology
Onkológiai Osztály
Ophtalmology
Pulmonológia
Pulmonológiai Osztály
Szemészeti Osztály

Clinical trials at this site (55)

Search interface

Extension Study for Participants in Studies That Include Pembrolizumab Recruiting

2022-501254-10-00 Advanced tumors 5 2018-08-24
A randomized study to evaluate the Efficacy and Safety of Intravitreal EYE103 Compared to Anti-VEGF Ended

2025-520809-12-00 Diabetic Macular Edema 10 2025-10-16
LUCIA: A Phase 3 randomized, double-masked study comparing the efficacy of EYP-1901 against aflibercept Ended

2024-518030-83-00 Wet age-related macular degeneration (wAMD) 5 2025-06-05
A study to test whether BI 764524 helps people with an eye condition called diabetic retinopathy Ended

2023-508891-12-00 Diabetic retinopathy 4 2024-11-28
A randomized study to evaluate the Efficacy and Safety of Intravitreal EYE103 Compared to Anti-VEGF (in patients with Diabetic Macular Edema… Ended

2024-510944-30-00 Diabetic Macular Edema 10 2024-11-22
A Phase 3 Study of DB-1303 vs Investigator's Choice Chemotherapy in HER2-low, Hormone Receptor Positive, Metastatic Breast Cancer Ended

2023-507333-17-00 HER2-low, Hormone Receptor Positive, Metastatic Breast 5 2024-04-15
A randomized, double-blind, placebo-controlled multicenter study to evaluate the effect of inclisiran on preventing major adverse cardiovasc… Ended

2022-502779-40-00 Primary prevention of atherosclerotic cardiovascular di 5 2023-09-04
A trial to learn how well Dato-DXd works and how safe it is compared to standard chemotherapy in adults with triple-negative breast cancer (… Ended

2023-509260-25-00 Locally Recurrent Inoperable or Metastatic Triple-negat 5 2022-07-12
A randomized, double-blind, Phase III Study of AZD9833 plus CDK4/6 inhibitor in patients with metastatic breast cancer with detectable ESR1 … Ended

2023-503990-39-00 Estrogen Receptor-Positive, HER-2 negative Advanced Bre 5 2021-09-30
Comparing Paclitaxel-Carboplatin-Oregovomab versus Paclitaxel-Carboplatin-Placebo in Patients with Advanced Ovarian Cancer Ended

2024-519218-30-00 Advanced epithelial ovarian, fallopian tube or peritone 5 2021-05-26
A Randomised, Double-Blind, Phase III Study of AZD9833 plus Palbociclib versus Anastrozole plus Palbociclib in Patients with ER-Positive HER… Ended

2023-503995-26-00 Estrogen Receptor-Positive, HER2-Negative Advanced Brea 5 2021-05-11
Avelumab Program Rollover Study Ended

2024-514274-46-00 Solid Tumors 5 2019-06-21
A phase III multi-center, randomized, open-label trial to evaluate efficacy and safety of ribociclib with endocrine therapy as adjuvant trea… Ended

2023-510357-42-00 hormone receptor (HR)-positive, HER2-negative, early br 5 2019-05-22
Corticotrophin Releasing Factor 2 Agonist For the Treatment of Worsening Heart Failure (WHF) – The CRAFT-WHF Study Halted

2024-518951-52-00 Worsening Heart Failure 4 2025-11-12
A Trial to Investigate TransCon TLR7/8 Agonist in Combination with Pembrolizumab, TransCon TLR7/8 Agonist in Combination with TransCon IL-2 … Ended

2023-506092-10-00 Stage III-IVA Resectable Locoregionall Advanced Head an 4 2024-03-11
A study to test whether BI 765845 helps people who have had a heart attack Ended

2022-502788-39-00 acute myocardial infarction 4 2023-11-27
REIMAGINE 2: A research study to see how well CagriSema compared to semaglutide, cagrilintide and placebo lowers blood sugar and body weight… Ended

2022-502678-18-00 Type 2 diabetes 5 2023-11-07
A Study of Retatrutide (LY3437943) in Participants With Obesity and Cardiovascular Disease (TRIUMPH-3) Ended

2023-503659-88-00 Cardiovascular Disease 5 2023-09-05
A study to evaluate Intravitreal JNJ-81201887(AAVCAGsCD59) Compared to Sham Procedure for the Treatment of Geographic Atrophy (GA) Secondary… Ended

2022-500746-16-00 Geographic Atrophy 4 2023-08-11
Dapagliflozin and Effect on Cardiovascular Events in Acute Heart Failure -Thrombolysis in Myocardial Infarction 68 (DAPA ACT HF-TIMI 68) Ended

2024-517612-29-00 acute heart failure 11 2023-02-14
A study to test asundexian for preventing a stroke caused by a clot in participants after an acute ischemic stroke or after a high-risk tran… Ended

2023-503793-20-00 Prevention of ischemic stroke in patients post acute no 5 2023-01-18
A Phase 3, randomized, double-blind, placebo-controlled, multicenter study of IV FDY-5301 in patients with a myocardial infarction (STEMI) Ended

2024-514372-40-00 Anterior ST-Elevation Myocardial Infarction 5 2022-04-12
A clinical study of OPT-302 with aflibercept compared to aflibercept alone in patients with neovascular age-related macular degeneration Ended

2024-512880-30-00 Neovascular Age-related Macular Degeneration (wet AMD) 5 2021-08-27
Phase 2 First-Line ES-SCLC Platform Study Ended

2023-506538-56-00 First-line treatment of participants with extensive-sta 4 2021-08-12